A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 1 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 26, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Drug: Calderasib; Biological: Durvalumab; Other: Placebo to MK-1084
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- The main inclusion criteria include but are not limited to the following:
- Has a histological or cytological diagnosis of locally advanced, unresected Stage II (node-positive) to III non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology.
- Has completed definitive platinum-based concurrent chemoradiotherapy (CCRT) prior to enrollment, without disease progression.
- Has provided a tumor tissue sample for central laboratory testing of Kirsten rat sarcoma G12C (KRAS G12C) status, programmed cell death ligand 1 (PD-L1) status, and biomarker research.
- Tumor tissue sample has a demonstrated presence of KRAS G12C mutation and an evaluable PD-L1 status result.
- If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART).
- If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy.
- If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
- Has a body weight ≥35 kg.
The main
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Low Country Cancer Care ( Site 0155)Savannah, Georgia
- Duly Healthcare ( Site 0158)Lisle, Illinois
- NHO Revive Research Institute LLC ( Site 0118)Lincoln, Nebraska
- New York Oncology Hematology P.C ( Site 9000)Albany, New York
- WakeMed Raleigh Campus ( Site 0144)Raleigh, North Carolina
- Virginia Cancer Specialists ( Site 0114)Fairfax, Virginia
- Instituto Alexander Fleming ( Site 0301)Ciudad Autonoma de Buenos Aires., Buenos Aires
- Hospital Italiano de Buenos Aires. ( Site 0300)Ciudad Autonoma de Buenos Aires, Buenos Aires
- Clinica Adventista Belgrano ( Site 0304)Ciudad Autonoma de Buenos Aires, Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303)Mar del Plata, Buenos Aires
- Hospital Britanico de Buenos Aires ( Site 0305)Buenos Aires, Buenos Aires F.D.
- Sanatorio Parque ( Site 0302)Rosario, Santa Fe Province
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 26, 2026. Always confirm current availability with the study team.